FDA Brief

Warning letters Food

FDA warning letter to

Guangzhou Sinocon Food Co., Ltd

High riskIssued Dec 23, 2024Posted Dec 31, 2024Human Foods Program

FDA warns Guangzhou Sinocon Food over food-safety violations in ready-to-eat Oat Beta Glucan powder, including pathogen hazards and inaccurate test certificates.

What happened

FDA inspected the company’s food manufacturing facility in Guangzhou, China, on March 18-19, 2024, covering ready-to-eat Oat Beta Glucan powder. FDA found the hazard analysis did not treat recontamination with environmental pathogens after sterilization as needing a required control, and that environmental monitoring did not test for Salmonella or an indicator organism. FDA also found Certificates of Analysis reported negative Salmonella and S. aureus results for some lots even when those lots had not been tested.

What FDA found

  1. The hazard analysis did not consider whether recontamination with environmental pathogens at steps after sterilization needed a required control to prevent contamination.

    21 CFR 117.130(a)(1)
  2. The hazard analysis named Salmonella, Staphylococcus aureus, and coliforms at a processing step but did not treat them as hazards needing a control to prevent contamination.

    21 CFR 117.130(a)(1)
  3. Certificates of Analysis stated that some lots tested negative for Salmonella and S. aureus even though the lots had not been tested.

    21 CFR 117.305(b) and (d)
  4. The company did not test the environment for Salmonella or a suitable indicator organism when contamination with an environmental pathogen was a hazard needing a control.

    21 CFR 117.165(a)(3)
  5. The environmental monitoring program did not identify the analytical tests to be conducted, including the analytical methods used.

    21 CFR 117.165(b)(3)(v)

What FDA wants

FDA asks the company to respond in writing within 15 working days with specific corrective steps and documentation, including a timetable if actions will take longer, and to explain with support if it believes its products do not violate the Act.

Who should pay attention

  • U.S. buyers of ready-to-eat powdered food ingredients
  • companies relying on Certificates of Analysis from this supplier
  • contract manufacturers and brands sharing low-moisture food equipment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk